For the quarter ending 2026-03-31, BCRX made $156,413K in revenue. -$722,218K in net income. Net profit margin of -461.74%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 156,413 | 406,555 | 159,395 | 163,353 |
| Cost of product sales | 5,377 | 9,522 | 2,187 | 2,798 |
| Acquired in-process research and development | 697,761 | - | - | - |
| Research and development | 60,319 | 40,867 | 44,603 | 43,386 |
| Selling, general and administrative | 94,554 | 95,781 | 83,014 | 87,383 |
| Total operating expenses | 858,011 | 146,170 | 129,804 | 133,567 |
| (loss) income from operations | -701,598 | 260,385 | 29,591 | 29,786 |
| Interest income | 2,256 | 2,890 | 2,238 | 2,516 |
| Interest expense | 19,779 | 12,257* | 19,661 | 21,582 |
| Foreign currency (losses) gains, net | -225 | -125 | 35 | -63 |
| Loss on extinguishment of debt | - | -6,965* | -2,740 | -4,171 |
| Other income | - | 4,089* | 2,667 | - |
| Other expense, net | -1,462 | - | - | - |
| Total other expense, net | -19,210 | -12,368 | -17,461 | -23,300 |
| (loss) income before income taxes | -720,808 | 248,017 | 12,130 | 6,486 |
| Income tax expense | 1,004 | 2,172 | -769 | 1,401 |
| Net (loss) income | -721,812 | 245,845 | 12,899 | 5,085 |
| Foreign currency translation adjustment | -62 | -1,219 | -523 | 702 |
| Unrealized gain on available for sale investments | -344 | 117 | 17 | -188 |
| Total other comprehensive (loss) income | -406 | -1,102 | -506 | 514 |
| Net comprehensive (loss) income | -722,218 | 244,743 | 12,393 | 5,599 |
| Basic EPS | -2.98 | 1.16 | 0.06 | 0.02 |
| Diluted EPS | -2.98 | 1.116 | 0.06 | 0.02 |
| Basic Average Shares | 242,258,000 | 210,995,000 | 210,176,000 | 209,519,000 |
| Diluted Average Shares | 242,258,000 | 219,292,000 | 219,885,000 | 219,886,000 |
BIOCRYST PHARMACEUTICALS INC (BCRX)
BIOCRYST PHARMACEUTICALS INC (BCRX)